ClinicalTrials.gg
RecruitingNCT04209504Updated Oct 15, 2026

Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block

An observational study in Shoulder Surgery, Shoulder Pain and Shoulder Injuries, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.

Planned enrollment
13th of 24
60 · median 65
Started
2021
with 8 others
Observational
24 of 146
6 open now
Primary completion
2027-08
later than 18 of 27 live
Registered
100th of 146
by date
Lead sponsor
4 of 146
Duke University

Among the 146 studies in Shoulder Pain with a site in United States, this one is the 13th largest by planned enrollment of the 24 observational ones that give a count, is one of 9 that started in 2021, is one of 24 observational ones, reaches primary completion later than 18 of the 27 other live ones, and was the 100th registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Shoulder Pain with a site in United States, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate the incidence of hemidiaphragmatic paralysis in patients receiving interscalene brachial plexus nerve block with prolonged neural blockade. English speaking American Society of Anesthesiologists (ASA) 1-3 patients ages 18-80 receiving prolonged interscalene nerve block will be randomized into 3 groups: first group receiving a perineural catheter infusing 0.2% ropivacaine; the second group receiving a single shot injection of 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine and the third receiving 20mL liposomal bupivacaine plus 5mL bupivacaine (to be determined by the attending anesthesiologist).Primary outcome will be incidence of hemidiaphragmatic paralysis postoperative day 1 as measured by point of care (POCUS) ultrasound.

Read the detailed description

This prospective observational study aims to evaluate the incidence of hemidiaphragmatic paralysis in patients receiving interscalene brachial plexus nerve block with prolonged neural blockade. English speaking ASA 1-3 patients ages 18-80 receiving prolonged interscalene nerve block will be randomized into 3 groups first group receiving a perineural catheter infusing 0.2% ropivacaine; the second group receiving a single shot injection of 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine and the third group receiving 20mL liposomal bupivacaine plus 5mL bupivacaine (to be determined by the attending anesthesiologist). Primary outcome will be incidence of hemidiaphragmatic paralysis postoperative day 1 as measured by point of care (POCUS) ultrasound. Secondary outcomes include incidence of hemidiaphragmatic paralysis as measured by point of care ultrasound (POCUS) in the immediate postoperative period, postoperative day (POD) 1, POD2, and POD3 and noninvasive measures of pulmonary gas exchange at pre-op, post-op, POD1, POD2, and POD3. Additionally, the investigators will look at pain scores (scale of 0-10) and opioid consumption (in oral morphine equivalents) at previously defined time points listed above. Furthermore, the investigators will record known side effects of interscalene blocks including hoarseness and Horner's syndrome.

03

Conditions studied

  • Shoulder Surgery
  • Shoulder Pain
  • Shoulder Injuries
  • Shoulder Arthritis
  • Shoulder Disease
  • Rotator Cuff Tears
  • Rotator Cuff Injuries
  • Rotator Cuff Arthropathy of Left Shoulder
  • Rotator Cuff Arthropathy of Right Shoulder
  • Rotator Cuff Repair

Keywords

  • Rotator Cuff Repair
  • Shoulder Surgery
  • Hemidiaphragmatic paralysis
  • Interscalene Block
  • Interscalene Catheter
  • Interscalene Liposomal Bupivacaine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients ages 18-80 undergoing shoulder surgery per standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking 18-80 year old ASA 1-3 patients
  • Primary shoulder surgery
  • Must live within a 25 mile radius

Exclusion criteria

Exclusion Criteria:

  • ASA 4 or 5
  • Revision shoulder surgery
  • Diagnosis of chronic pain
  • Daily chronic opioid use (over 3 months of continuous opioid use)
  • Inability to communicate pain scores or need for analgesia
  • Infection at the site of block placement
  • Age under 18 years old or greater than 80 years old
  • Pregnant women (as determined by point-of-care serum bHCG)
  • Intolerance/allergy to local anesthetics
  • Weight \<50 kg
  • > 40
  • severe pulmonary disease including and restrictive lung disease
  • Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  • Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance.
  • Current or historical evidence of any disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Continuous Perineural Catheter

    Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.

    Diagnostic Test: Ultrasound · Drug: Ropivacaine · Device: MediPines AGM100 Advanced Respiratory Monitoring System

  • 10 mL Liposomal Bupivacaine Single Shot

    Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine

    Diagnostic Test: Ultrasound · Drug: Bupivacaine · Device: MediPines AGM100 Advanced Respiratory Monitoring System

  • 20 mL Liposomal Bupivacaine Single Shot

    Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine

    Diagnostic Test: Ultrasound · Drug: Bupivacaine · Device: MediPines AGM100 Advanced Respiratory Monitoring System

Interventions

  • Diagnostic testUltrasound

    Ultrasound guided evaluation of diaphragm ipsilateral to the block side.

  • Local anesthetic (numbing drug)

    Also known as: Naropin

  • Local anesthetic (numbing drug)

    Also known as: Liposomal bupivacaine, Exparel, Marcaine

  • DeviceMediPines AGM100 Advanced Respiratory Monitoring System

    Non-invasive respiratory monitor to measure oxygenation and ventilation parameters

    Also known as: non-invasive respiratory monitor

06

What researchers measure

Primary outcomes

  1. Hemidiaphragmatic paralysis - ipsilateral - postoperative day (POD) 1

    Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis POD1

    Time frame: 24 hours

Secondary outcomes

  1. Hemidiaphragmatic paralysis - ipsilateral - PACU, POD2, POD3

    Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis in PACU, POD2, and POD 3

    Time frame: up to 72 hours

  2. Noninvasive pulmonary measures of gas exchange

    Noninvasive pulmonary measures of gas exchange

    Time frame: up to 72 hours

  3. Pain scores

    Numerical Rating Scale (NRS) 11 pain scores (0-10; 0=no pain, 10=worst pain ever) at Post Anesthesia Care Unit (PACU), POD1, POD2, POD3

    Time frame: up to 72 hours

  4. Opioid consumption

    Opioid consumption in Oral Morphine Equivalents (OMEs) at PACU, POD1, POD2, POD3

    Time frame: up to 72 hours

  5. Hoarseness

    Incidence of recurrent laryngeal nerve palsy (subjective)

    Time frame: up to 72 hours

  6. Horner's Syndrome

    Incidence of Horner's Syndrome

    Time frame: up to 72 hours

07

Study locations

1 of 1 sites recruiting
  • Duke University Hospital
    Durham, North Carolina 27710, United States
    Recruiting
    • William M Bullock, MD, PhD · Contactwilliam.bullock@duke.edu · 919-681-6437
    • Amanda Kumar, MD · Contactamanda.kumar@duke.edu · 919-681-6437
    • Amanda Kumar, MD · Principal investigator
    • William M Bullock, MD, PhD · Sub investigator
    • Jeff C Gadsden, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used once patient has completed the study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Aug 2027, 70 months after the start.

Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's planned 70 months is above that.

Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2019
First posted
Dec 24, 2019
StartActual
Oct 12, 2021
Primary completionEst.
Aug 31, 2027was Aug 2026
CompletionEst.
Aug 31, 2027was Aug 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Aug 31, 2027
Oct 15, 2026
Study completion
Aug 31, 2026→Aug 31, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Aug 31, 2026→Aug 31, 2027
    Study completion Aug 31, 2026→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04209504
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Oct 12, 2021
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

WIlliam M Bullock, MD, PhD
Contact
william.bullock@duke.edu
919-681-6437
Amanda Kumar, MD
Contact
amanda.kumar@duke.edu
919-681-6437
Amanda Kumar, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion